Overview

A Study in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA): - The safety of LY2439821 and any side effects that might be associated with it. - Whether LY2439821 can help participants with active RA. - How much LY2439821 should be given to participants.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ixekizumab